CAESAREA, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- XACT Robotics Ltd. today announced that the European Patent Office (EPO) will grant a patent expanding the Company’s patent portfolio to include the use of its robotic system in ultrasound-guided interventional procedures.
“As part of our vision of democratizing interventional procedures, our robotic system will be compatible with all imaging modalities, allowing physicians to provide the ultimate care for their patients. The recent patent is another testimony to the uniqueness of our technology. It allows us to continue to protect our assets globally which now include the use of ultrasound, after having already obtained corresponding patents in the U.S. and China”, according to XACT’s CEO, Chen Levin.
Including this latest notification, the Company has 14 issued patents and 58 patent applications pending worldwide. The Company already obtained CE Certification for the use of its robotic system with CT, and is in the process of receiving FDA approval later this year.
XACT Robotics develops a truly transformational technology – the first and only robotic system that combines navigation with steering and insertion capabilities to be used in soft-tissue interventional percutaneous procedures. The XACT system delivers any surgical and/or procedural tool to the desired anatomical target with unparalleled accuracy and consistency, allowing more physicians to treat more patients by democratizing interventional procedures.
XACT Robotics Ltd, 8 Hatochen St, PO Box 3097, CAESAREA 3079861, Israel
OFFICE: +972-4-770-0153 FAX: +972-4-770-0161 EMAIL: INFO@XACTROBOTICS.COM